DR JOHN KELLER

Board of Directors member

Dr John Keller joined Shionogi Inc. in July 2010 and was appointed as President and Chief Executive Officer and as a member of the Shionogi Inc. Board of Directors in April 2011.


Immediately prior to joining Shionogi, John was a Partner in SR One, the venture capital group of GlaxoSmithKline. Previously, John served as Executive Vice President and Chief Business Officer of Incyte Corporation, playing a key role in its transformation into a drug discovery and development company and establishing its first major corporate alliance after that transformation. Before Incyte, John had a 16-year tenure at GlaxoSmithKline and its predecessor, SmithKline Beecham, culminating in the position of Vice President, Worldwide Business Development. In that role, he structured numerous licensing agreements with a broad range of partners worldwide, including the agreements originally establishing the Shionogi-GSK (later Shionogi-ViiV Healthcare) joint venture. Earlier positions encompassed R&D strategy, technology licensing, alliance management, public policy, project management, and drug discovery research.


John holds a Ph.D. in microbiology from Rutgers University and a Bachelor's degree in biology from Johns Hopkins University.

YOU MAY ALSO BE INTERESTED IN

We are ViiV Healthcare: 100% dedicated to HIV medicines and research and focused on people living with HIV and AIDS.

Together we are engaged in the HIV response throughout the world, supported by a team of over 1,100 dedicated ViiV Healthcare staff working across the globe.

Discover more about who we are, the work we do and what we're doing to advance HIV science, support the delivery of HIV treatment and care; and work with partners to address the stigma and discrimination faced by people living with HIV.